spacer
home > ebr > spring 2019 > trusting in biobanking
PUBLICATIONS
European Biopharmaceutical Review

Trusting in Biobanking

Biobanking is used to create large scale repositories of human biological material, such as blood, urine, tissue, and DNA, to further medical research. Research institutes, hospitals, and biopharmaceutical and biotechnology companies rely on biobanks to advance research of new therapies and for the identification of disease biomarkers from large patient cohorts. Biobanking supports a number of modern research techniques, including genomics and personalised medicine, by allowing researchers to better understand who is most at risk of certain diseases and what treatments they may best respond to. A number of biobanks exist worldwide, each containing hundreds of thousands of samples to contribute to the growing pool of knowledge and safeguarding public health in future generations.

Nuclear Magnetic Resonance and Biobanking

Sample collection, preparation, analysis, storage, transport, and data management must all be highly standardised in biobanking. Samples that are stored over decades can change, and researchers can never guarantee that a sample will remain unchanged over time. The high reproducibility of nuclear magnetic resonance (NMR) spectroscopy makes it an important analytical tool for biobank samples. It can characterise stored samples and determine whether any changes could lead to artefacts.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Matthias Nauck is a Professor at the Institute of Clinical Chemistry at University Medicine Greifswald, Germany. His role is split between a focus on patient care and a range of scientific research projects. Matthias has played an integral role in introducing NMR to the lab at Greifswald for epidemiological research and biobanking studies.
spacer
Matthias Nauck
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma Celebrates 15 Years of Growth and Success

Vilnius, Lithuania, July 16, 2019 ─ Northway Biotechpharma, a leading biopharmaceutical contract development and manufacturing organization (CDMO), celebrates its 15th anniversary today. As a midsized CDMO, Northway Biotechpharma is able to provide flexibility and responsiveness backed by a strong foundation in science and technology. The company focuses on understanding its customers and meeting their specific needs without binding them to one single approach. It is able to react rapidly to unexpected project changes, adjusting timelines, capacities and other activities to meet its customers’ evolving needs. On average, Northway Biotechpharma has 25–30 development projects underway each year, ranging from gene cloning to final drug product manufacturing.
More info >>

White Papers

Soothing the Logistical Headache of Clinical Trials

Equilibrium Travel Management

As many as 30 per cent of subjects on phase three clinical studies drop out.  Gruelling schedules, high travel costs and time waiting for expense reimbursement can all be factors in these fall rates, and this can be very problematic, delaying or even leading to the cancellation of the trial.  It is crucial to keep subjects motivated, and through efficient travel and expense management, this can be achieved.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement